1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Depression: Evidence of serotonin signal transduction disturbances

By RoboCodeine7610, Sep 6, 2015 | |
  1. RoboCodeine7610

    Depression and anxiety disorders are the most common psychiatric disorders. Over the last few years, molecular brain imaging using Positron Emission Tomography (PET) has helped us to identify important mechanisms involved in the development and treatment of these disorders, particularly those associated with the serotonin neurotransmitter system. The drugs that are used for these conditions (SSRIs) were developed 30 years ago. To celebrate this anniversary, a team from MedUni Vienna, led by Siegfried Kasper, Director of the University Department of Psychiatry and Psychotherapy, has summarised the latest status of global research in this field in The Lancet Psychiatry.

    "People laughed at us when we started treating depression with SSRIs (selective serotonin reuptake inhibitors) 30 years ago," explains Siegfried Kasper, who is also one of the pioneers of this method of treatment. "Today it is State of the Art and we are able to quantify disturbances in serotonin signal transmission in the brain as the cause of depression and anxiety disorders." 80% of those suffering from depression are treated with SSRIs -- the success rate is around 70%. Kasper: "Their quality of life is enhanced and there is a significant and lasting improvement in their motivation and mood."

    Quantifiable mechanisms

    Using Positron Emission Tomography (PET) from nuclear medicine, it is possible to quantify receptors, transporters and enzymes, in order to diagnose neurochemical differences in brain disorders but also to make a detailed analysis of the effects a drug has on the brain.

    For example, it was also shown that the level of serotonin transporter (SERT) is greatly reduced in certain parts of the brain in patients with depression. At the same time, PET showed that SSRIs are a very effective pharmacological first-line therapy that brings about specific changes in the activity of the serotonin system. The serotonin transporter (SERT) is a cell membrane protein that facilitates return of the neurotransmitter serotonin (commonly known as the "happy hormone") into the cell. The activity of the serotonin transporter influences neural networks in the brain that are changed in depression. The serotonin transporter therefore also serves as a point of attack for the main antidepressants, such as SSRIs.

    The current study is the result of a collaboration with the Neurobiology Research Unit of Copenhagen University Hospital. Rupert Lanzenberger's research group at the University Department of Psychiatry and Psychotherapy, under the direction of Siegfried Kasper, is one of the leading international research teams in the field of PET brain imaging in psychiatric disorders. The underlying mechanisms for this were investigated in Vienna, in collaboration with the University Department of Radiology and Nuclear Medicine.

    The study will also be discussed at the Congress of the European College of Neuropsychopharmacology, which starts this coming Friday and runs until 1 September.

    Medical University of Vienna.
    ScienceDaily, 26 August 2015.
    http://www.sciencedaily.com/releases/2015/08/150826082138.htm

Comments

To make a comment simply sign up and become a member!